BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• News

  Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

  July 11, 2024

   · 

  5 min read
• Press Releases

  First Patient Dosed in Phase I Clinical Trial of YOLT-201

  July 11, 2024

   · 

  3 min read
• 

  Drug Pricing

  FTC to Sue ‘Big Three’ PBMs for Setting Insulin, Other Drug Prices: WSJ

  The Federal Trade Commission plans to file lawsuits against the three largest pharmacy benefit managers over allegedly steering patients away from less expensive drugs, according to The Wall Street Journal.

  July 11, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

  July 11, 2024

   · 

  8 min read
• Press Releases

  Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

  July 11, 2024

   · 

  5 min read
• 

  Complete Response Letters

  FDA Rejects Novo’s Once-Weekly Insulin Injection, Cites Manufacturing Process

  The FDA’s Complete Response Letter turned down Novo Nordisk’s Biologics License Application for its once-weekly basal insulin icodec injection for diabetes mellitus, with “requests” related to the manufacturing process and the type 1 diabetes indication.

  July 11, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Imidex and Spesana Form Strategic Partnership to Impact Early Lung Cancer Detection and Patient Outcomes

  July 11, 2024

   · 

  2 min read
• 

  Press Releases

  FDA Approved PDE4 Inhibitor Roflumilast for Atopic Dermatitis

  On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions in the U.S.

  July 11, 2024

   · 

  1 min read
• Press Releases

  Synamics Therapeutics, AI-Driven Drug Discovery Startup, Attracts Former Novozymes Executives as Lead Investors

  July 11, 2024

   · 

  2 min read
• Press Releases

  PIM Kinases As Therapeutic Targets For Cancer Drug Development

  July 11, 2024

   · 

  4 min read